Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined with Capecitabine in Advanced HCC
NCT03114085Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
Phase 2, randomised, open-label trial of capecitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Time to Progression at 2 years. Status: unknown.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03114085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114085.